605 related articles for article (PubMed ID: 11158191)
1. Association of African-American ethnic background with survival in men with metastatic prostate cancer.
Thompson I; Tangen C; Tolcher A; Crawford E; Eisenberger M; Moinpour C
J Natl Cancer Inst; 2001 Feb; 93(3):219-25. PubMed ID: 11158191
[TBL] [Abstract][Full Text] [Related]
2. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials.
Roach M; Lu J; Pilepich MV; Asbell SO; Mohiuddin M; Grignon D
J Urol; 2003 Jan; 169(1):245-50. PubMed ID: 12478146
[TBL] [Abstract][Full Text] [Related]
3. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.
Albain KS; Unger JM; Crowley JJ; Coltman CA; Hershman DL
J Natl Cancer Inst; 2009 Jul; 101(14):984-92. PubMed ID: 19584328
[TBL] [Abstract][Full Text] [Related]
4. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
[TBL] [Abstract][Full Text] [Related]
5. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning.
Glass TR; Tangen CM; Crawford ED; Thompson I
J Urol; 2003 Jan; 169(1):164-9. PubMed ID: 12478127
[TBL] [Abstract][Full Text] [Related]
6. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.
Halabi S; Ou SS; Vogelzang NJ; Small EJ
Cancer; 2007 Oct; 110(7):1478-84. PubMed ID: 17665494
[TBL] [Abstract][Full Text] [Related]
7. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999.
Underwood W; Jackson J; Wei JT; Dunn R; Baker E; Demonner S; Wood DP
Cancer; 2005 Feb; 103(3):538-45. PubMed ID: 15612083
[TBL] [Abstract][Full Text] [Related]
8. Impact of race on survival in men with metastatic hormone-refractory prostate cancer.
Halabi S; Small EJ; Vogelzang NJ; Barrier RC; George SL; Gilligan TD
Urology; 2004 Aug; 64(2):212-7. PubMed ID: 15302462
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation.
Zagars GK; Pollack A; Pettaway CA
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):517-23. PubMed ID: 9806509
[TBL] [Abstract][Full Text] [Related]
10. Racial Disparities in the Presentation, Early Definitive Surgical Treatment, and Mortality Among Men Diagnosed with Poorly Differentiated/Undifferentiated Non-metastatic Prostate Cancer in the USA.
Lediju O; Ikuemonisan J; Salami SS; Adejoro O
J Racial Ethn Health Disparities; 2019 Apr; 6(2):401-408. PubMed ID: 30506310
[TBL] [Abstract][Full Text] [Related]
11. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
[TBL] [Abstract][Full Text] [Related]
12. Re: Association of African-American ethnic background with survival in men with metastatic prostate cancer.
Polednak AP
J Natl Cancer Inst; 2001 Aug; 93(15):1174-5. PubMed ID: 11481391
[No Abstract] [Full Text] [Related]
13. Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity.
Underwood W; Wei J; Rubin MA; Montie JE; Resh J; Sanda MG
Urol Oncol; 2004; 22(1):20-4. PubMed ID: 14969799
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease.
Powell IJ; Banerjee M; Novallo M; Sakr W; Grignon D; Wood DP; Pontes JE
Urology; 2000 Feb; 55(2):246-51. PubMed ID: 10688088
[TBL] [Abstract][Full Text] [Related]
15. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.
Bernard B; Muralidhar V; Chen YH; Sridhar SS; Mitchell EP; Pettaway CA; Carducci MA; Nguyen PL; Sweeney CJ
Cancer; 2017 May; 123(9):1536-1544. PubMed ID: 28055108
[TBL] [Abstract][Full Text] [Related]
16. The association between presentation PSA and race in two sequential time periods in prostate cancer patients seen at a university hospital and its community affiliates.
Pan CC; Lee JS; Chan JL; Sandler HM; Underwood W; McLaughlin PW
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1292-6. PubMed ID: 14630264
[TBL] [Abstract][Full Text] [Related]
17. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
Sylvester RJ; Denis L; de Voogt H
Eur Urol; 1998; 33(2):134-43. PubMed ID: 9519354
[TBL] [Abstract][Full Text] [Related]
18. Investigating Black-White differences in prostate cancer prognosis: A systematic review and meta-analysis.
Evans S; Metcalfe C; Ibrahim F; Persad R; Ben-Shlomo Y
Int J Cancer; 2008 Jul; 123(2):430-435. PubMed ID: 18452170
[TBL] [Abstract][Full Text] [Related]
19. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
D'Amico AV; Moul JW; Carroll PR; Cote K; Sun L; Lubeck D; Renshaw AA; Loffredo M; Chen MH
J Natl Cancer Inst; 2004 Apr; 96(7):509-15. PubMed ID: 15069112
[TBL] [Abstract][Full Text] [Related]
20. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
